The recent publication by Medicines sans Frontiers entitled ‘Fatal imbalance: the crisis in research and development for drugs for neglected diseases’ has caused considerable interest in the press.[1] The report describes the research and development activities of eleven major pharmaceutical companies, representing combined sales of nearly $117bn (£78bn). In the...